RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs.
In both research and therapeutic applications of RNA interference, it is often advantageous to silence several targets simultaneously. Toward this end, several groups have developed vectors that utilize the model of endogenously encoded micro (mi) RNAs, where a single RNA polymerase II promoter can drive the expression of multiple interfering RNAs. Stronger pol III promoters have been used to drive individual short hairpin (sh) RNAs, but to date, it has been necessary to repeat the promoter in each silencing cassette to achieve multiplexed expression from a single vector. Here, we show that it is possible to drive polycistronic expression from a single pol III promoter when the interfering RNAs are formatted to resemble miRNAs rather than shRNAs. As many as four miRNAs designed to target hepatitis B virus (HBV) transcripts are shown to be processed and functional in reporter assays as well as in the context of replicating virus in cell culture systems. Although it has been observed that high levels of expression of shRNAs can lead to cytotoxicity, we find no significant evidence in transient transfection assays that the HBV-miRNAs produced by our vectors compete for the activity of endogenously produced miR-122 or for processing of an exogenously expressed miR-EGFP.
Snyder
Lindsey L
LL
Department of Microbiology and Immunology, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Ahmed
Iqbal
I
Steel
Laura F
LF
D045744:Cell Line, Tumor; D006515:Hepatitis B virus / Q000235:genetics / Q000502:physiology; D006801:Humans; D035683:MicroRNAs / Q000737:chemistry / Q000378:metabolism; D011401:Promoter Regions, Genetic; D034622:RNA Interference; D012320:RNA Polymerase III / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000737:chemistry / Q000378:metabolism; D014779:Virus Replication
D035683:MicroRNAs; D034741:RNA, Small Interfering; D012320:RNA Polymerase III
Mol Ther. 2007 Mar;15(3):534-41
17213835
Gene Ther. 2006 Jun;13(11):883-92
16496015
Biotechniques. 2006 Jul;41(1):64-8
16869515
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5868-73
18398004
Nucleic Acids Res. 2006;34(16):4467-76
16945958
Mol Ther. 2009 Mar;17(3):538-47
19088704
J Gene Med. 2007 Jul;9(7):620-34
17486668
Mol Ther. 2007 May;15(5):878-88
17311009
J Virol. 2005 Feb;79(3):1645-54
15650190
Mol Ther. 2009 Jan;17(1):169-75
19002161
EMBO J. 2004 Oct 13;23(20):4051-60
15372072
Mol Ther. 2005 Nov;12(5):900-9
16115802
Nucleic Acids Res. 2007;35(19):6598-610
17905815
Nat Struct Mol Biol. 2006 Dec;13(12):1097-101
17099701
J Gene Med. 2008 Oct;10(10):1059-70
18642399
Mol Ther. 2006 Dec;14(6):883-92
16959541
Mol Ther. 2006 Oct;14(4):485-93
16872906
Cell. 2006 Jun 2;125(5):887-901
16751099
PLoS One. 2008 Jul 02;3(7):e2602
18596982
Cell. 2006 Jun 16;125(6):1111-24
16777601
Nucleic Acids Res. 2008 May;36(9):2811-24
18346971
RNA Biol. 2004 Jul;1(2):106-13
17179747
J Virol. 2004 Apr;78(7):3436-46
15016866
J Virol. 2005 Jun;79(11):7050-8
15890944
Biotechniques. 2006 Jul;41(1):59-63
16869514
EMBO Rep. 2003 Jun;4(6):609-15
12776180
Mol Ther. 2008 Mar;16(3):557-564
28178502
Gene Ther. 2009 Jan;16(1):142-7
18701917
RNA. 2004 Dec;10(12):1957-66
15525708
Virus Res. 2006 Jun;118(1-2):150-5
16423421
Oncogene. 2006 Jun 26;25(27):3857-65
16799627
Nucleic Acids Res. 2007;35(15):5154-64
17660190
Biochem Biophys Res Commun. 2008 Sep 19;374(2):214-8
18619945
J Gene Med. 2006 Apr;8(4):433-41
16389634
Antiviral Res. 2008 Oct;80(1):36-44
18499277
Gene Ther. 2008 Dec;15(23):1536-49
18800151
Mol Ther. 2006 Oct;14(4):494-504
16844419
Nucleic Acids Res. 2006 Apr 13;34(7):e53
16614444
Nature. 2006 May 25;441(7092):537-41
16724069
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1927-32
14762164